Ohemaa Kwakyi

Ms. Ohemaa Kwakyi

Royal College of Surgeons in Ireland, University of Medicine and Health Sciences
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2019 in Multiple Sclerosis Journal
Verified
Journal Article
Closed access
PDF file
OMOlwen C Murphy
Olwen C Murphy
OKOhemaa Kwakyi
Ohemaa Kwakyi
MIMustafa Iftikhar
Mustafa Iftikhar
SZSidra Zafar
Sidra Zafar
JLJeffrey Lambe
Jeffrey Lambe
SSShiv Saidha
Shiv Saidha
Background: The retinal vasculature may be altered in multiple sclerosis (MS), potentially acting as a biomarker of disease processes. Objective: To compare retinal vascular plexus densities in people with MS (PwMS) and healthy controls (HCs), and examine correlations with visual function and global disability. Methods: In this cross-sectional study, 111 PwMS (201 eyes) and 50 HCs (97 eyes) underwent optical coherence tomography angiography (OCTA). Macular superficial vascular plexus (SVP) and deep vascular plexus (DVP) densities were quantified, and poor quality images were excluded according to an artifact-rating protocol. Results: Mean SVP density was 24.1% (SD = 5.5) in MS eyes (26.0% (SD = 4.7) in non-optic neuritis (ON) eyes vs. 21.7% (SD = 5.5) in ON eyes, p < 0.001), as compared to 29.2% (SD = 3.3) in HC eyes ( p < 0.001 for all MS eyes and multiple sclerosis optic neuritis (MSON) eyes vs. HC eyes, p = 0.03 for MS non-ON eyes vs. HC eyes). DVP density did not differ between groups. In PwMS, lower SVP density was associated with higher levels of disability (expanded disability status scale (EDSS): R2 = 0.26, p = 0.004; multiple sclerosis functional composite (MSFC): R2 = 0.27, p = 0.03) and lower letter acuity scores (100% contrast: R2 = 0.29; 2.5% contrast: R2 = 0.40; 1.25% contrast: R2 = 0.31; p < 0.001 for all). Conclusions: Retinal SVP density measured by OCTA is reduced across MS eyes, and correlates with visual function, EDSS, and MSFC scores.

11 October 2018 in Brain
Verified
Journal Article
Closed access
NCNatalia Gonzalez Caldito
Natalia Gonzalez Caldito
SSShiv Saidha
Shiv Saidha
ESElias S Sotirchos
Elias S Sotirchos
BDBlake E Dewey
Blake E Dewey
NCNorah J Cowley
Norah J Cowley
PCPeter A Calabresi
Peter A Calabresi
On average, African Americans with multiple sclerosis demonstrate higher inflammatory disease activity, faster disability accumulation, greater visual dysfunction, more pronounced brain tissue damage and higher lesion volume loads compared to Caucasian Americans with multiple sclerosis. Neurodegeneration is an important component of multiple sclerosis, which in part accounts for the clinical heterogeneity of the disease. Brain atrophy appears to be widespread, although it is becoming increasingly recognized that regional substructure atrophy may be of greater clinical relevance. Patient race (within the limitations of self-identified ancestry) is regarded as an important contributing factor. However, there is a paucity of studies examining differences in neurodegeneration and brain substructure volumes over time in African Americans relative to Caucasian American patients. Optical coherence tomography is a non-invasive and reliable tool for measuring structural retinal changes. Recent studies support its utility for tracking neurodegeneration and disease progression in vivo in multiple sclerosis. Relative to Caucasian Americans, African American patients have been found to have greater retinal structural injury in the inner retinal layers. Increased thickness of the inner nuclear layer and the presence of microcystoid macular pathology at baseline predict clinical and radiological inflammatory activity, although whether race plays a role in these changes has not been investigated. Similarly, assessment of outer retinal changes according to race in multiple sclerosis remains incompletely characterized. Twenty-two African Americans and 60 matched Caucasian Americans with multiple sclerosis were evaluated with brain MRI, and 116 African Americans and 116 matched Caucasian Americans with multiple sclerosis were monitored with optical coherence tomography over a mean duration of 4.5 years. Mixed-effects linear regression models were used in statistical analyses. Grey matter (-0.9%/year versus -0.5%: P =0.02), white matter (-0.7%/year versus -0.3%: P =0.04) and nuclear thalamic (-1.5%/year versus -0.7%/year: P =0.02) atrophy rates were approximately twice as fast in African Americans. African Americans also exhibited higher proportions of microcystoid macular pathology (12.1% versus 0.9%, P =0.001). Retinal nerve fibre layer (-1.1% versus -0.8%: P =0.02) and ganglion cell+ inner plexiform layer (-0.7%/year versus -0.4%/year: P =0.01) atrophy rates were faster in African versus Caucasian Americans. African Americans on average exhibited more rapid neurodegeneration than Caucasian Americans and had significantly faster brain and retinal tissue loss. These results corroborate the more rapid clinical progression reported to occur, in general, in African Americans with multiple sclerosis and support the need for future studies involving African Americans in order to identify individual differences in treatment responses in multiple sclerosis.

20 April 2021 in Neurology
Verified
Journal Article
Closed access
PDF file
JLJeffrey Lambe
Jeffrey Lambe
KFKathryn Fitzgerald
Kathryn Fitzgerald
OMOlwen C. Murphy
Olwen C. Murphy
AFAngeliki Filippatou
Angeliki Filippatou
ESElias S. Sotirchos
Elias S. Sotirchos
PCPeter A Calabresi
Peter A Calabresi
Objective To evaluate whether a retinal spectral-domain optical coherence tomography (SD-OCT) assessment at baseline is associated with long-term disability worsening in people with multiple sclerosis (PwMS), we performed SD-OCT and Expanded Disability Status Scale (EDSS) assessments among 132 PwMS at baseline and at a median of 10 years later. Methods In this prospective, longitudinal study, participants underwent SD-OCT, EDSS, and visual acuity (VA) assessments at baseline and at follow-up. Statistical analyses were performed using generalized linear regression models, adjusted for age, sex, race, multiple sclerosis (MS) subtype, and baseline disability. We defined clinically meaningful EDSS worsening as an increase of ≥2.0 if baseline EDSS score was <6.0 or an increase of ≥1.0 if baseline EDSS score was ≥6.0. Results A total of 132 PwMS (mean age 43 years; 106 patients with relapsing-remitting MS) were included in analyses. Median duration of follow-up was 10.4 years. In multivariable models excluding eyes with prior optic neuritis, relative to patients with an average baseline ganglion cell + inner plexiform layer (GCIPL) thickness ≥70 µm (the mean GCIPL thickness of all eyes at baseline), an average baseline GCIPL thickness <70 µm was associated with a 4-fold increased odds of meaningful EDSS worsening (adjusted odds ratio [OR] 3.97, 95% confidence interval [CI] 1.24–12.70; p = 0.02) and an almost 3-fold increased odds of low-contrast VA worsening (adjusted OR 2.93, 95% CI 1.40–6.13; p = 0.04). Conclusions Lower baseline GCIPL thickness on SD-OCT is independently associated with long-term disability worsening in MS. Accordingly, SD-OCT at a single time point may help guide therapeutic decision-making among individual PwMS. Classification of Evidence This study provides Class I evidence that lower baseline GCIPL thickness on SD-OCT is independently associated with long-term disability worsening in MS.

15 December 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ADAdrian Dervan
Adrian Dervan
AFAntonio Franchi
Antonio Franchi
FAFrancisco R. Almeida-Gonzalez
Francisco R. Almeida-Gonzalez
Jennifer DowlingJennifer Dowling
Jennifer Dowling
OKOhemaa Kwakyi
Ohemaa Kwakyi
AHAlan Hibbitts
Alan Hibbitts
Injury to the peripheral or central nervous systems often results in extensive loss of motor and sensory function that can greatly diminish quality of life. In both cases, macrophage infiltration into the injury site plays an integral role in the host tissue inflammatory response. In particular, the temporally related transition of macrophage phenotype between the M1/M2 inflammatory/repair states is critical for successful tissue repair. In recent years, biomaterial implants have emerged as a novel approach to bridge lesion sites and provide a growth-inductive environment for regenerating axons. This has more recently seen these two areas of research increasingly intersecting in the creation of ‘immune-modulatory’ biomaterials. These synthetic or naturally derived materials are fabricated to drive macrophages towards a pro-repair phenotype. This review considers the macrophage-mediated inflammatory events that occur following nervous tissue injury and outlines the latest developments in biomaterial-based strategies to influence macrophage phenotype and enhance repair.

11 February 2019 in Multiple Sclerosis Journal
Verified
Journal Article
Closed access
PDF file
ESElias S Sotirchos
Elias S Sotirchos
NGNatalia Gonzalez-Caldito
Natalia Gonzalez-Caldito
BDBlake E Dewey
Blake E Dewey
KFKathryn Fitzgerald
Kathryn Fitzgerald
JGJeffrey Glaister
Jeffrey Glaister
SSShiv Saidha
Shiv Saidha
The effects of disease-modifying therapies (DMTs) on region-specific brain atrophy in multiple sclerosis (MS) are unclear. To determine the effects of higher versus lower efficacy DMTs on rates of brain substructure atrophy in MS. A non-randomized, observational cohort of people with MS followed with annual brain magnetic resonance imaging (MRI) was evaluated retrospectively. Whole brain, subcortical gray matter (GM), cortical GM, and cerebral white matter (WM) volume fractions were obtained. DMTs were categorized as higher (DMT-H: natalizumab and rituximab) or lower (DMT-L: interferon-beta and glatiramer acetate) efficacy. Follow-up epochs were analyzed if participants had been on a DMT for ⩾6 months prior to baseline and had at least one follow-up MRI while on DMTs in the same category. A total of 86 DMT epochs (DMT-H: n = 32; DMT-L: n = 54) from 78 participants fulfilled the study inclusion criteria. Mean follow-up was 2.4 years. Annualized rates of thalamic (−0.15% vs −0.81%; p = 0.001) and putaminal (−0.27% vs −0.73%; p = 0.001) atrophy were slower during DMT-H compared to DMT-L epochs. These results remained significant in multivariate analyses including demographics, clinical characteristics, and T2 lesion volume. DMT-H treatment may be associated with slower rates of subcortical GM atrophy, especially of the thalamus and putamen. Thalamic and putaminal volumes are promising imaging biomarkers in MS.

28 January 2019 in Current Eye Research
Verified
Journal Article
Closed access
MIMustafa Iftikhar
Mustafa Iftikhar
SZSidra Zafar
Sidra Zafar
NGNatalia Gonzalez
Natalia Gonzalez
OMOlwen Murphy
Olwen Murphy
OKOhemaa Kwakyi
Ohemaa Kwakyi
RCRoomasa Channa
Roomasa Channa
Purpose: To evaluate artifacts in optical coherence tomography angiography (OCT-A) images of multiple sclerosis (MS) patients and healthy controls. Materials and methods: This was a prospective cross-sectional study conducted at the Department of Neurology and the Wilmer Eye Institute at Johns Hopkins Hospital. Subjects included patients with an established diagnosis of MS and healthy volunteers. OCT-A was performed using Spectralis® OCT-A prototype, OCT2 (Heidelberg, Germany). The type and frequency of artifacts, the clinical factors associated with them, and their impact on vessel density measurements were assessed. Results: Overall, 385 images from 102 participants were analyzed. The majority of images (97.1%) had some degree of artifact. The most frequent was motion artifact (96.3%), followed by blinking (51.9%), and loss of focus (25.1%). MS patients were more likely to have any artifact vs. controls (OR [95% CI], 3.83 [1.12–12.92]), and were more likely to have motion artifacts with longer disease duration (OR [95% CI], 1.11 [1.03–1.20]) or history of optic neuritis (OR [95% CI], 4.24 [1.19–15.16]). The relative area occupied by the artifact was found to underestimate vessel density measurements in both MS patients and controls. Conclusions: Artifacts are common with OCT-A imaging using this particular Spectralis® OCT-A prototype and can impact quantitative vascular density metrics. Future studies should review images for artifacts before drawing definitive conclusions